Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.
Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
Sep 20, 2022
Goldie Hawn to lead discussion on supporting mental health around the globe with preeminent C-suite executives, politicians, nonprofit leaders and entrepreneurs on the importance of mental health SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 20, 2022-- Vistagen (Nasdaq: VTGN), a late
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
Sep 19, 2022
In healthy subjects, intranasal administration of PH94B activated nasal chemosensory cells, rapidly reduced sympathetic tone, and provided rapid self-reported calmness SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 19, 2022-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
Sep 08, 2022
Independent biostatisticians recommend continuing PALISADE-2 without any changes after conducting interim analysis of 140 completed subjects Topline data for PALISADE-2 trial expected in the first half of 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc.